IMNN Key Statistics, Chart & Performance
The current stock price of IMNN is 3.14 USD. In the past month the price decreased by -21.01%. In the past year, price decreased by -73.36%.
IMNN Technical Analysis
IMNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMNN. The financial health of IMNN is average, but there are quite some concerns on its profitability.
IMNN Financial Highlights
Over the last trailing twelve months IMNN reported a non-GAAP Earnings per Share(EPS) of -11.25. The EPS increased by 54.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -159.43% | ||
| ROE | -351.06% | ||
| Debt/Equity | 0 |
IMNN Forecast & Estimates
10 analysts have analysed IMNN and the average price target is 65.18 USD. This implies a price increase of 1975.8% is expected in the next year compared to the current price of 3.14.
IMNN Ownership
IMNN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.97 | 383.716B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.75 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.79 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.69 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.19 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.35 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMNN
Company Profile
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Company Info
IMUNON INC
997 Lenox Dr Ste 100
Lawrenceville NEW JERSEY US
Employees: 25
Phone: 16098969100
IMUNON INC / IMNN FAQ
Can you describe the business of IMUNON INC?
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
What is the current price of IMNN stock?
The current stock price of IMNN is 3.14 USD. The price increased by 0.64% in the last trading session.
Does IMUNON INC pay dividends?
IMNN does not pay a dividend.
What is the ChartMill rating of IMUNON INC stock?
IMNN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy IMNN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMNN.
What is the employee count for IMNN stock?
IMUNON INC (IMNN) currently has 25 employees.
Can you provide the upcoming earnings date for IMUNON INC?
IMUNON INC (IMNN) will report earnings on 2026-02-25, after the market close.